NASH

[Communications Biology] Researchers performed whole-genome sequencing on clonally expanded single liver stem cells cultured as intrahepatic cholangiocyte organoids from patients with alcoholic cirrhosis, non-alcoholic steatohepatitis, and primary sclerosing cholangitis.

[Hepatic Cell News] Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.

[iScience] Investigators implicated that glucosylceramide accumulation was one of triggers promoting the development of nonalcoholic fatty liver disease into non-alcoholic steatohepatitis, then, fibrosis and tumorigenesis.

[Nature Reviews Immunology] Scientists discussed current concepts related to the role of immune cells in the onset and progression of non-alcoholic steatohepatitis.

[BMC Research Notes] Scientists evaluated whether placental extract influences epithelial–mesenchymal transition (EMT) and fibrosis through cytokine-induced EMT in the retinal pigment epithelial cells, in vitro.

[Gannex Pharma Co., Ltd.] Gannex Pharma Co., Ltd. announced the Investigational New Drug (IND) application approval by US FDA and initiation of global development of ASC43F, a fixed-dose combination with dual targets of thyroid hormone receptor beta and farnesoid X receptor for the treatment of non-alcoholic steatohepatitis (NASH).